Skip to main content
SpringerLink
Log in

Risk of Antipsychotic Drug Use in Patients with Alzheimer’s Disease Treated with Rivastigmine

  • Original Research Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Background and Objective: Cholinesterase inhibitors may offer some improvement in the behavioural symptoms of Alzheimer’s disease. The dual inhibitory mechanism of action of rivastigmine (inhibition of acetylcholinesterase and butyrylcholinesterase) may improve behavioural symptoms and may delay the need for antipsychotics. This study was conducted to investigate the effect of rivastigmine on the time to first antipsychotic drug use among patients with Alzheimer’s disease, compared with patients with Alzheimer’s disease not treated with a cholinesterase inhibitor.

Design and Methods: This study used MarketScan® research databases from 1 January 1999 to 31 March 2002. Patients were included if they: (a) were diagnosed with Alzheimer’s disease on two occasions or filled a prescription for rivastigmine for the first time during the index period from 1 July 2000 to 31 December 2001; (b) were 65 years of age and older; (c) had continuous health and prescription insurance coverage during the entire study period; and (d) had not used an antipsychotic medication within 18 months prior to their index Alzheimer’s disease prescription or diagnosis. The ‘no cholinesterase inhibitor’ group included patients who were newly diagnosed with Alzheimer’s disease, but did not use any cholinesterase inhibitors. Chi-square, Student’s t-, and log-rank tests were used to test differences in study variables between groups. Cox proportional hazards models were used to estimate predicted risk of first antipsychotic drug use.

Results: The study included 497 patients in the rivastigmine group and 749 patients in the ‘no cholinesterase inhibitor’ group. The rivastigmine group patients were younger compared with the ‘no cholinesterase inhibitor’ group patients (p < 0.01). The overall usage of antipsychotics was considerably lower for patients taking rivastigmine (9.8%) compared with those not taking cholinesterase inhibitors (25.6%). Patients taking rivastigmine were 64% less likely (relative risk = 0.36; p < 0.0001) to take antipsychotics compared with patients not taking cholinesterase inhibitors, after adjusting for demographic covariates, comorbid conditions, and use of other CNS drugs and anticonvulsants. Age was the only other factor that influenced antipsychotic use; older patients were significantly more likely to start antipsychotics than younger patients.

Conclusion: This study provides initial evidence that patients with Alzheimer’s disease treated with rivastigmine have a reduced risk of initiating therapy with an antipsychotic drug compared with patients who receive no cholinesterase inhibitor treatment. These findings may imply that rivastigmine use could delay the onset of behavioural symptoms that require treatment with antipsychotic medications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1
Table III

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Yanker BA, Mesulam MM. Beta-amyloid and the pathogenesis of Alzheimer’s disease. N Engl J Med 1991; 325(26): 1849–57

    Article  Google Scholar 

  2. Evans DA, Funkenstein HH, Albert MS, et al. Prevalence of Alzheimer’s disease in a community population of older persons: higher than previously reported. JAMA 1989; 262(18): 2551–6

    Article  PubMed  CAS  Google Scholar 

  3. Miech RA, Breitner JC, Zandi PP, et al. Incidence of AD may decline in the early 90s for men, later for women: The Cache County Study. Neurology 2002; 58(2): 209–18

    Article  PubMed  CAS  Google Scholar 

  4. Minino AM, Arias E, Kochanek KD, et al. Deaths: final data for 2000. Natl Vital Stat Rep 2002; 50(15): 1–120

    PubMed  Google Scholar 

  5. Richards SS, Hendrie HC. Diagnosis, management, and treatment of Alzheimer’s disease. Arch Intern Med 1999; 159: 789–98

    Article  PubMed  CAS  Google Scholar 

  6. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984; 34(7): 939–44

    Article  PubMed  CAS  Google Scholar 

  7. Highlights from the annual scientific assembly: managing the stages of Alzheimer’s disease — new management options. South Med J 2002; 95(1): 102–6

    Google Scholar 

  8. Levy ML, Cummings JL, Fairbanks LA, et al. Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer’s disease. Am J Psychiatry 1996; 153(11): 1438–43

    PubMed  CAS  Google Scholar 

  9. Coen RF, Swanwick GRJ, O’Boyle CA, et al. Behaviorial disturbance and other predictors of carer burden in Alzheimer’s disease. Int J Geriatr Psychiatry 1997; 12: 331–6

    Article  PubMed  CAS  Google Scholar 

  10. Rymer S, Salloway S, Norton L, et al. Impaired awareness, behaviorial disturbance, and caregiver burden in Alzheimer disease. Alzheimer Dis Assoc Disord 2002; 16(4): 248–53

    Article  PubMed  Google Scholar 

  11. Robert P. Understanding and managing behavioral symptoms in Alzheimer’s disease and related dementias: focus on rivastigmine. Curr Med Res Opin 2002; 18(3): 156–77

    Article  PubMed  CAS  Google Scholar 

  12. Schneider LS. New therapeutic approaches to Alzheimer’s disease. J Clin Psychiatry 1996; 57Suppl. 14: 30–6

    PubMed  CAS  Google Scholar 

  13. Krall WJ, Sramek JJ, Cutler NR. Cholinesterase inhibitors: a therapeutic strategy for Alzheimer’s disease. Ann Pharmacother 1999; 33: 441–50

    Article  PubMed  CAS  Google Scholar 

  14. Giacobini E. Cholinesterase inhibitors stabilize Alzheimer’s Disease. Ann N Y Acad Sci 2000; 920: 321–7

    Article  PubMed  CAS  Google Scholar 

  15. Barner EL, Gray SL. Donepezil use in Alzheimer’s disease. Ann Pharmacother 1998; 32: 70–7

    Article  PubMed  CAS  Google Scholar 

  16. Huserau D, Wolfson C, Shukla V. Drug treatments for Alzheimer’s disease: efficacy, outcome measurements and cost-effectiveness. Ottawa (ON): Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 2001 Jul. Technology Overview No. 4

    Google Scholar 

  17. National Institute for Clinical Excellence. Guidance on the use of donepezil, rivastigmine, and galantamine for the treatment of Alzheimer’s disease. London: National Institute for Clinical Excellence; 2001 Jan. Technology Appraisal Guidance No. 19

    Google Scholar 

  18. Raskind MA, Peskind ER. Alzheimer’s disease and related disorders. Med Clin North Am 2001; 85(3): 803–17

    Article  PubMed  CAS  Google Scholar 

  19. Lawlor B, Bhriain SN. Psychosis and behavioral symptoms of dementia: defining the role of neuroleptics. Int J Geriatr Psychiatry 2001; 16: S2–6

    Article  PubMed  Google Scholar 

  20. Daniel DG. Antipsychotic treatment of psychosis and agitation in the elderly. J Clin Psychiatry 2000; 61Suppl. 14: 49–52

    PubMed  CAS  Google Scholar 

  21. Tariot PN. Treatment strategies for agitation and psychosis in dementia. J Clin Psychiatry 1996; 57Suppl. 14: 21–9

    PubMed  CAS  Google Scholar 

  22. Lopez OL, Wisniewski SR, Becker JT, et al. Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease. Arch Neurol 1999; 56(10): 1266–72

    Article  PubMed  CAS  Google Scholar 

  23. Rosier M, Retz W, Retz-Junginger P, et al. Effect of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioral symptoms in Alzheimer’s disease. Behav Neurol 1998; 11(4): 211–6

    Google Scholar 

  24. Inglis F, Sim A, Russell E. Behavioral benefits observed with rivastigmine in Alzheimer’s disease [abstract]. Int Psychogeriatr 2001; 13Suppl. 2: 236S

    Google Scholar 

  25. Mega MS, Masterman DM, O’Connor SM, et al. The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. Arch Neurol 1999; 56(11): 1388–93

    Article  PubMed  CAS  Google Scholar 

  26. Bullock R, Moulais R, Steinwachs KC, et al. Effects of rivastigmine on behavioral symptoms in nursing home patients with Alzheimer’s disease [abstract]. Int Psychogeriatr 2001; 13Suppl. 2: 242S

    Google Scholar 

  27. Etemad B. Behavioral and cognitive benefits of rivastigmine in nursing home patients: a 26 week follow up [abstract]. Int Psychogeriatr 2001; 13Suppl. 2: 241S

    Google Scholar 

  28. Cummings J, Anand R, Koumaras B, et al. Rivastigmine provides behavioral benefits to Alzheimer’s disease patients residing in a nursing home: findings from a 26-week trial. Neurology 2000; 54Suppl. 3: A468–9

    Google Scholar 

  29. Greig NH, Lahiri DK, Sambamurti K. Butyrylcholinesterase: an important new target in Alzheminer’s disease therapy. Int Psychogeriatr 2002; 14Suppl. 1: 77–91

    Article  PubMed  Google Scholar 

  30. Grossberg GT. The ABC of Alzheimer’s disease: behavioral symptoms and their treatment. Int Psychogeriatr 2002; 14Suppl. 1: 27–49

    Article  PubMed  Google Scholar 

  31. Bullock R. The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis. Int J Clin Pract 2002; 56: 206–14

    PubMed  CAS  Google Scholar 

  32. American Society of Health-System Pharmacists. American hospital formulary service drug information. Bethesda (MD): American Society of Health-System Pharmacists, 2002

    Google Scholar 

  33. Klein JP, Moeschberger ML. Survival analysis: techniques for censored and truncated data. New York: Springer-Verlag Inc, 1997

    Google Scholar 

  34. Gambassi G, Landi F, Lapane KL, et al. Predictors of mortality in patients with Alzheimer’s disease living in nursing homes. J Neurol Neurosurg Psychiatry 1999; 67: 59–65

    Article  PubMed  CAS  Google Scholar 

  35. Weiner M, Powe NR, Weiler WE, et al. Alzheimer’s disease under managed care: implications from Medicare utilization and expenditure patterns. J Am Geriatr Soc 1998; 46(6): 762–70

    PubMed  CAS  Google Scholar 

  36. Collett D. Modelling survival data in medical research. New York: Chapman & Hall, 1994

    Google Scholar 

  37. SAS Institute Inc. SAS/STAT user’s guide. Version 8. Cary (NC): SAS Institute, 1999

    Google Scholar 

  38. Small GW, Donohue JA, Brooks RL. An economic evaluation of donepezil in the treatment of Alzheimer’s disease. Clin Ther 1998; 20(4): 838–50

    Article  PubMed  CAS  Google Scholar 

  39. Cummings JL. Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry 2000; 157(1): 4–15

    PubMed  CAS  Google Scholar 

  40. Cummings JL. Guidelines for managing Alzheimer’s disease (Pt II): treatment. Am Fam Physician 2002; 65(12): 2525–34

    PubMed  Google Scholar 

  41. Wennberg JE, Roos N, Sola L, et al. Use of claims data systems to evaluate health care outcomes: mortality and reoperation following prostatectomy. JAMA 1987; 257(7): 933–6

    Article  PubMed  CAS  Google Scholar 

  42. Newcomer R, Clay T, Luxenberg JS, et al. Misclassification and selection bias when identifying Alzheimer’s disease solely from Medicare claims records. J Am Geriatr Soc 1999; 47(2): 215–9

    PubMed  CAS  Google Scholar 

  43. Taylor DH, Fillenbaum GG, Ezell ME. The accuracy of medicare claims data in identifying Alzheimer’s disease. J Clin Epidemiol 2002; 55: 929–37

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This study was partially supported by Novartis Pharmaceuticals Corporation.

Author information

Authors and Affiliations

  1. Ernest Mario School of Pharmacy, Rutgers University, 160 Frelinghuysen Road, Piscataway, New Jersey, 08854, USA

    Dong-Churl Suh, Christopher Powers & Hyunchul Shin

  2. Health Economics and Outcomes Research, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA

    Stephen Arcona & Simu K. Thomas

  3. US Clinical Development and Medical Affairs, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA

    Adrian L. Rabinowicz & Dario Mirski

Authors
  1. Dong-Churl Suh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen Arcona
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Simu K. Thomas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christopher Powers
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Adrian L. Rabinowicz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hyunchul Shin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Dario Mirski
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dong-Churl Suh.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Suh, DC., Arcona, S., Thomas, S.K. et al. Risk of Antipsychotic Drug Use in Patients with Alzheimer’s Disease Treated with Rivastigmine. Drugs Aging 21, 395–403 (2004). https://doi.org/10.2165/00002512-200421060-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200421060-00004

Keywords

Search

Navigation